Inclusion Criteria:

Disease Characteristics:

1. Patient previously diagnosed with MM;

2. Progressive disease. For non-secretory multiple myeloma, progressive disease is
defined as bone marrow biopsy with > 25% increase in plasma cells or an absolute
increase of at least 10% over prior known level. Alternatively, development of new or
worsening of existing lytic bone lesions or soft tissue plasmacytomas, or
hypercalcemia (serum calcium >11.5 mg/dL), or relapse from CR.

Patient Characteristics:

1. 18 yrs or older

2. Patient has given voluntary written informed consent.

3. Unless post-menopausal or surgically sterilized, a female must be willing to use an
acceptable method of birth control

4. Male patient must agree to use an acceptable method for contraception for the
duration of the study.

5. ECOG Performance Status 0-2.

6. Life expectancy is at least 3 months.

7. • ANC over 1,000/ul without the use of colony stimulating factors

- Platelets over 50,000/ul without transfusion support 7 days

- Bilirubin 2.0 mg/dl or less

- AST 4 times or less upper limit normal Prior Therapy for Multiple Myeloma:
Patients must have had at least 2 prior therapeutic regimens

Exclusion Criteria:

- Pregnant or breast feeding

- History of allergic reaction to compounds containing boron or mannitol.

- Active uncontrolled viral (including HIV), bacterial, or fungal infection.

- Grade III or IV toxicity due to previous anti-neoplastic therapy

- More than Grade 2 motor or sensory neuropathy

- MI within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV
heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or
electrocardiographic evidence of acute ischemia.

- For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2,
patients with LVEF less than 35% by MUGA.

- Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single
or two drug combinations of these are permissible)

- Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy

- Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)